UniQure/CSL hit by FDA clinical hold for hem B gene therapy program after liver cancer find

Just two weeks after showing off positive results at the American Society of Hematology (ASH) meeting, uniQure and partner CSL have been hit with an FDA clinical hold for their bleeding disease treatment etranacogene dezaparvovec.

The gene therapy has been in trials for hemophilia B in the hope it could provide a one-and-done approach to effectively curing the condition.